Molnupiravir

Kathryn Dzintars, Pharm.D., BCPS
Molnupiravir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) for the emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 disease in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 disease, including hospitalization and death.

  • Risk for progression includes: age > 60 years, diabetes, obesity (BMI ≥ 30), chronic kidney disease, serious heart conditions, chronic obstructive pulmonary disease, or active cancer.
  • Authorized for treatment within the first 5d of symptomatic COVID-19 illness.

Molnupiravir is NOT authorized for:

  • Patients < 18 years of age
  • Patients requiring hospitalization for the management of COVID-19 disease (benefit has not been observed in patients beginning treatment after hospitalization)
  • Use longer than 5 consecutive days
  • Pre-exposure or post-exposure prophylaxis for the prevention of COVID-19 disease

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

The FDA issued an Emergency Use Authorization (EUA) for the emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 disease in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 disease, including hospitalization and death.

  • Risk for progression includes: age > 60 years, diabetes, obesity (BMI ≥ 30), chronic kidney disease, serious heart conditions, chronic obstructive pulmonary disease, or active cancer.
  • Authorized for treatment within the first 5d of symptomatic COVID-19 illness.

Molnupiravir is NOT authorized for:

  • Patients < 18 years of age
  • Patients requiring hospitalization for the management of COVID-19 disease (benefit has not been observed in patients beginning treatment after hospitalization)
  • Use longer than 5 consecutive days
  • Pre-exposure or post-exposure prophylaxis for the prevention of COVID-19 disease

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: January 4, 2022